KR102731953B1 - Mica/b 항체 및 사용 방법 - Google Patents

Mica/b 항체 및 사용 방법 Download PDF

Info

Publication number
KR102731953B1
KR102731953B1 KR1020207023978A KR20207023978A KR102731953B1 KR 102731953 B1 KR102731953 B1 KR 102731953B1 KR 1020207023978 A KR1020207023978 A KR 1020207023978A KR 20207023978 A KR20207023978 A KR 20207023978A KR 102731953 B1 KR102731953 B1 KR 102731953B1
Authority
KR
South Korea
Prior art keywords
delete delete
amino acid
acid sequence
seq
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207023978A
Other languages
English (en)
Korean (ko)
Other versions
KR20200115545A (ko
Inventor
네일 깁슨
저스틴 채프만
신 두
Original Assignee
컬리난 미카 코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 컬리난 미카 코퍼레이션 filed Critical 컬리난 미카 코퍼레이션
Publication of KR20200115545A publication Critical patent/KR20200115545A/ko
Application granted granted Critical
Publication of KR102731953B1 publication Critical patent/KR102731953B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/844—Liver
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020207023978A 2018-01-25 2019-01-24 Mica/b 항체 및 사용 방법 Active KR102731953B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862621892P 2018-01-25 2018-01-25
US62/621,892 2018-01-25
PCT/US2019/015025 WO2019147863A2 (en) 2018-01-25 2019-01-24 Mica/b antibodies and methods of use

Publications (2)

Publication Number Publication Date
KR20200115545A KR20200115545A (ko) 2020-10-07
KR102731953B1 true KR102731953B1 (ko) 2024-11-20

Family

ID=67396240

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207023978A Active KR102731953B1 (ko) 2018-01-25 2019-01-24 Mica/b 항체 및 사용 방법

Country Status (10)

Country Link
US (2) US20210047417A1 (https=)
EP (1) EP3743109A4 (https=)
JP (2) JP7458993B2 (https=)
KR (1) KR102731953B1 (https=)
CN (1) CN112566659A (https=)
AU (1) AU2019211411B2 (https=)
BR (1) BR112020015142A2 (https=)
IL (1) IL276187B1 (https=)
MX (1) MX2020007880A (https=)
WO (1) WO2019147863A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3768715A1 (en) 2018-03-23 2021-01-27 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
MX2021001254A (es) 2018-07-31 2021-05-12 Cullinan Mica Corp Anticuerpos anti-mica/b que bloquean la liberación de mica/b y métodos de uso.
WO2020035345A1 (en) 2018-08-14 2020-02-20 Innate Pharma Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody
CA3186062A1 (en) * 2020-08-10 2022-02-17 Marion BENEZECH Cell surface mica and micb detection using antibodies
CN114369161B (zh) * 2021-12-28 2023-06-23 合肥天港免疫药物有限公司 Mica抗体及其应用
CN114369162B (zh) * 2021-12-28 2023-05-30 合肥天港免疫药物有限公司 抗体及其应用
JP2025512137A (ja) * 2022-04-08 2025-04-16 ディーツーエム バイオセラピューティクス リミテッド 抗ｍｉｃａ／ｂ抗体及びその使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013049517A2 (en) 2011-09-30 2013-04-04 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
WO2014140904A2 (en) * 2013-03-15 2014-09-18 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1857116A1 (en) * 2006-05-19 2007-11-21 Novoplant GmbH Antigen binding polypeptides against spike glycoprotein (S2) of bovine coronavirus
BRPI0808551B1 (pt) * 2007-03-01 2022-04-05 Symphogen A/S Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
US8753640B2 (en) * 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
WO2015003114A1 (en) * 2013-07-05 2015-01-08 University Of Washington Through Its Center For Commercialization Soluble mic neutralizing monoclonal antibody for treating cancer
KR102206029B1 (ko) * 2014-01-27 2021-01-20 삼성전자주식회사 Ang-2에 특이적으로 결합하는 항체 및 그의 용도
KR102763121B1 (ko) * 2015-02-06 2025-02-04 내셔널 유니버시티 오브 싱가포르 치료적 면역 세포의 효능의 향상 방법
US11780924B2 (en) * 2016-06-21 2023-10-10 University Of Oslo HLA binding vaccine moieties and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013049517A2 (en) 2011-09-30 2013-04-04 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
WO2014140904A2 (en) * 2013-03-15 2014-09-18 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins

Also Published As

Publication number Publication date
JP2024038169A (ja) 2024-03-19
JP7458993B2 (ja) 2024-04-01
US20210047417A1 (en) 2021-02-18
RU2020128010A (ru) 2022-02-25
AU2019211411B2 (en) 2025-11-27
JP2021511387A (ja) 2021-05-06
WO2019147863A3 (en) 2019-10-24
MX2020007880A (es) 2021-05-14
EP3743109A4 (en) 2021-11-10
CA3089478A1 (en) 2019-08-01
BR112020015142A2 (pt) 2021-01-05
US20240067731A1 (en) 2024-02-29
KR20200115545A (ko) 2020-10-07
CN112566659A (zh) 2021-03-26
IL276187A (en) 2020-09-30
AU2019211411A1 (en) 2020-08-20
EP3743109A2 (en) 2020-12-02
WO2019147863A2 (en) 2019-08-01
IL276187B1 (en) 2026-02-01

Similar Documents

Publication Publication Date Title
KR102731953B1 (ko) Mica/b 항체 및 사용 방법
JP7734720B2 (ja) Ｍｉｃａ／ｂシェディングをブロックする抗ｍｉｃａ／ｂ抗体および使用方法
KR20170068458A (ko) 항-ｎｋｇ2ａ 항체를 사용한 치료 요법
HK1254289A1 (zh) 调控免疫反应的方法及抗体
JP2025004078A (ja) ４－１ｂｂ結合タンパク質及びその用途
KR20230019468A (ko) 비고전적 hla-i 및 신생항원을 포함하는 복합체를 표적화하는 항체 및 그의 사용 방법
JP7653532B2 (ja) 抗Ｓｉｇｌｅｃ１５抗体およびその使用
EP2373335B1 (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
US8541553B2 (en) Antibodies specific for the melanoma-associated endogenous retrovirus (MERV) envelope glycoprotein
US20220273809A1 (en) Axl antibody-drug conjugates for use in treating cancer
RU2821021C2 (ru) Антитела к mica/b и способы применения
RU2815101C2 (ru) Антитела против mica/b, блокирующие шеддинг mica/b, и способы их применения
CA3089478C (en) Mica/b antibodies and methods of use
BR112021001808B1 (pt) Anticorpo monoclonal ou um fragmento de ligação ao antígeno, composição farmacêutica e uso do referido anticorpo monoclonal ou fragmento
JP2025525073A (ja) エフェクター機能が増強された抗ｍｉｃａ／ｂ抗体および使用方法
KR101856904B1 (ko) Pauf 단백질에 특이적으로 결합하는 항체 및 이의 용도

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601